Literature DB >> 4039998

Temporal variation in the disposition of theophylline and its metabolites.

M V St-Pierre, M Spino, A F Isles, A Tesoro, S M MacLeod.   

Abstract

The temporal aspects of theophylline disposition are of interest, as there are predictable time-dependent fluctuations in the pulmonary function of patients with asthma and theophylline serum concentrations may vary throughout a 24-hour period. We studied the extent to which there are significant temporal changes in theophylline kinetics and the relative contribution of distribution, metabolism, and excretion to this phenomenon. Eight healthy men received an intravenous dose (6 mg/kg) of theophylline at 8 AM and 8 PM at 1-week intervals. Serum and urine were analyzed for theophylline and its three major metabolites by HPLC. Distribution volumes and total body and nonrenal clearances showed no differences between morning and evening dosing. The elimination rate was 12% greater after morning dosing. Renal clearance was 24% greater after morning dosing and was accompanied by an increased excretion fraction of unchanged theophylline. Based on total urinary metabolite excretion and the metabolite serum AUCs, there was no evidence of time-dependent variation in theophylline biotransformation. Although theophylline renal clearance is greater after morning dosing, it is only a small fraction of the overall drug elimination and does not change the total body clearance after morning or evening dosing.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4039998     DOI: 10.1038/clpt.1985.140

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Chronopharmacology and its application to the development of theophylline treatment schedules for asthma.

Authors:  K R Godfrey
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships.

Authors:  Pietro Fagiolino; Rosa Eiraldi; Marta Vázquez
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Bayesian derived predictions for twice daily theophylline under outpatient conditions and an assessment of optimal sampling times.

Authors:  H Chrystyn; J W Ellis; B A Mulley; M D Peake
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

4.  The effect of dosing time on the pharmacokinetics and pharmacodynamics of a 'once-a-day' sustained release theophylline preparation.

Authors:  H Lamont; R Pauwels; M Van der Straeten
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

5.  A theophylline dosage regimen which reduces round-the-clock variations in plasma concentrations resulting from diurnal pharmacokinetic variation.

Authors:  M B Regazzi; R Rondanelli; E Vida; F Farinelli; R A Upton
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.

Authors:  Sven Björkman
Journal:  Br J Clin Pharmacol       Date:  2005-06       Impact factor: 4.335

7.  Theophylline pharmacokinetics following single and repeated administration of slow-release capsules.

Authors:  J Torrent; I Izquierdo; M J Barbanoj; R Obach; M Nomen; F Jane
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

8.  A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.

Authors:  Alice Ban Ke; Srikanth C Nallani; Ping Zhao; Amin Rostami-Hodjegan; Nina Isoherranen; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2013-01-25       Impact factor: 3.922

Review 9.  Hypoxia, arterial pH and theophylline disposition.

Authors:  M Richer; Y W Lam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

10.  Pharmacokinetics of temafloxacin in humans after multiple oral doses.

Authors:  G R Granneman; P Carpentier; P J Morrison; A G Pernet
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.